Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Instruments Launches Viscosizer 200 - a New Analytical Instrument for Biopharmaceutical Development

Published: Thursday, August 01, 2013
Last Updated: Thursday, August 01, 2013
Bookmark and Share
Automated viscosity and molecular sizing using less than 10 µL sample.

The new Viscosizer 200 from Malvern Instruments is the latest product to reach commercialization as a result of Malvern’s highly focused Bioscience Development Initiative. Designed primarily to help solve key analytical challenges at the preformulation stage of pharmaceutical, and particularly biopharmaceutical, development, the automated Viscosizer 200 delivers viscosity and molecular size data on UV-active samples, using volumes of less than 10 µL.
 
Measuring viscosity early in the development of biological formulations is critical in order to reduce the number of candidate failures during subsequent stages of development. The Viscosizer 200 has been engineered to meet early development screening requirements which demand automated measurement on extremely low sample volumes, which should ideally be recoverable, as well as operation at high sample concentrations under formulation conditions.
 
The temperature-controlled Viscosizer 200 measures viscosity from 0.9 cP to 120 cP and hydrodynamic radius from 0.2 nm to 100 nm, in samples at concentrations from 0.1 mg/mL to >300 mg/mL. Its integrated carousel autosampler can be configured with a maximum of 45 vial positions.
 
The technology at the heart of the Viscosizer 200 is UV area imaging. This is used to monitor the time-dependent absorbance profile of UV-active samples such as proteins, peptides and other chromophore-containing molecules as they migrate through a microcapillary.
 
Capillary viscometry has long been used to determine viscosity from a simple measurement of time from injection to detector, but is subject to injection time errors that can result in significant errors in subsequent calculations. The Viscosizer 200 has a dual-pass capillary design whereby sample is detected at two windows along the capillary. This enables precise measurement of the transit time between windows and therefore of the sample’s viscosity relative to a reference, with demonstrable improvements over single-pass capillary systems.
 
For sizing analyses, as the sample migrates through the capillary, diffusion leads to broadening of the sample plug, a phenomenon countered by transverse diffusion: the smaller the molecule, the more rapid transverse diffusion and the less broadening of the peak. The Viscosizer 200 calculates mass-weighted mean hydrodynamic radius from the standard deviation of the sample profile at the two windows. UV wavelength selectivity means that the Viscosizer 200 can accurately measure the size of molecules of interest even within an excipient-laden formulation.
 
The Viscosizer 200 delivers to the demanding requirements of early biopharmaceutical development. It provides a unique analytical tool to support rapid understanding of the behavior of candidate molecules in various formulations, enabling important decisions on suitable formulations to be made as early as possible. The Viscosizer 200 also offers reliable size measurements for a variety of challenging applications in related fields.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Time at Pittcon for new Malvern Systems
Malvern is exhibiting its particle characterization and rheology ranges at Pittcon 2006.
Thursday, January 05, 2006
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!